Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Find generic entry opportunities
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
This chart shows the companies which have received the most GAIN Act exclusivities in the past five years.
The Generating Antibiotic Incentives Now Act provides for five years of market exclusivity for qualifying drugs.
The law defines qualifying drugs as 'an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections.'
Unlike most other regulatory extensions, which provide exclusivity starting from a drug's approval date, GAIN Act exclusivity provides an additional five years on top of any Hatch-Waxman exclusivity — even pediatric exclusivity, which extends an additional six months beyond patent protection.
The companies with the GAIN Act exclusivities are: